Tecan builds workstations for Italian biotech

29-Jul-2010

Siena Biotech, an Italian drug discovery company focused primarily on degenerative and proliferative diseases of the central nervous system, has chosen four Tecan Freedom EVO workstations for different roles in drug development. Built by the Swiss Tecan Integration Group (TIG), each system has been invaluable in increasing throughput and accuracy in testing compounds as potential therapeutic drugs.

Siena Biotech, an Italian drug discovery company focused primarily on degenerative and proliferative diseases of the central nervous system, has chosen four Tecan Freedom EVO workstations for different roles in drug development. Built by the Swiss Tecan Integration Group (TIG), each system has been invaluable in increasing throughput and accuracy in testing compounds as potential therapeutic drugs.

"We chose our Freedom EVO systems to improve throughput. We visited TIG and looked at all the possibilities for customisation, choosing the ones that best suited us. The instruments were then built in Switzerland before being integrated with our other systems on-site," said Marta Gherardi from Siena Biotech\'s compound management group.

Federico Cappelli, from the biomolecular screening group, added: "We are still at the early stages of setting up some of the different applications on our Freedom EVO system, and we are currently working on automating our Madin-Darby canine kidney (MDCK) cell line permeability assays in collaboration with the Met Profiling Group. The flexibility of the system will allow us to reproduce the results already obtained by a dedicated operator, increase the throughput and minimise inter-operator variability."

Tecan

Sign up for your free email newsletter

T +41 44 922 81 11
F +41 44 922 81 12
info@tecan.com

Companies